Related Experiment Video

Updated: Jun 17, 2026

Network Pharmacology and Validation of the Antidepressant Mechanisms of Qiangzhifang in a Chronic Restraint Stress-induced Depression Rat Model
08:15

Network Pharmacology and Validation of the Antidepressant Mechanisms of Qiangzhifang in a Chronic Restraint Stress-induced Depression Rat Model

Published on: June 6, 2025

Combating depression in Huntington's disease: effective antidepressive treatment with venlafaxine XR

Anna K Holl1, Leonora Wilkinson, Annamaria Painold

  • 1University Clinic of Psychiatry bUniversity Clinic of Neurosurgery, Graz Medical University, Auenbruggerplatz 31, Graz, Austria. anna.holl@klinikum-graz.at

International Clinical Psychopharmacology
|December 10, 2009
PubMed

Insights

Venlafaxine XR significantly reduced depression symptoms in Huntington

Area of Science:

  • Neuroscience
  • Psychiatry
  • Pharmacology

Background:

  • Huntington's disease (HD) frequently presents with psychiatric symptoms, including major depression.
  • Previous research on antidepressant efficacy in HD is limited to case studies.

Purpose of the Study:

  • To evaluate the effectiveness of venlafaxine XR in treating major depression in Huntington's disease patients.
  • To assess the safety and tolerability of venlafaxine XR in this population.

Main Methods:

  • A study involving 26 Huntington's disease patients diagnosed with major depression.
  • Systematic measurement of HD and depression symptoms using the Beck Depression Inventory and Hamilton Rating Scale for Depression.
  • Assessment at baseline and after 4 weeks of venlafaxine XR treatment.

Main Results:

  • Significant decrease in depression symptoms after 4 weeks of venlafaxine XR treatment.
  • Approximately 20% of patients experienced venlafaxine-related side effects, such as nausea and irritability.
  • Venlafaxine XR demonstrated high effectiveness in treating depression in HD patients.

Conclusions:

  • Venlafaxine XR is an effective treatment for major depression in Huntington's disease.
  • Potential for venlafaxine-related side effects necessitates careful monitoring.
  • Further research is needed to determine optimal depression management strategies for HD.

More Related Videos

Evaluating the Anti-depression Effect of Xiaoyaosan on Chronically-stressed Mice06:08

Evaluating the Anti-depression Effect of Xiaoyaosan on Chronically-stressed Mice

Published on: January 7, 2019

Related Concept Videos

Antidepressant Drugs: MAOIs and Other Agents01:23

Antidepressant Drugs: MAOIs and Other Agents

Atypical antidepressants, including bupropion (Wellbutrin), mirtazapine (Remeron), nefazodone (Serzone), trazodone (Desyrel), and vilazodone (Viibryd), offer unique mechanisms of action. Bupropion weakly inhibits dopamine and norepinephrine reuptake, aiding depression treatment and smoking cessation, with a low risk of sexual dysfunction. Mirtazapine enhances serotonin and norepinephrine neurotransmission, leading to sedation, increased appetite, and weight gain. As a result, it helps treat...
Antidepressant Drugs: Overview01:25

Antidepressant Drugs: Overview

Antidepressant drugs are a class of medications primarily used for treating various mood disorders, including major depression, anxiety disorders, and other related conditions. These medicines work by modulating the neurotransmitter balance within the brain, alleviating depressive symptoms. Antidepressants can be broadly categorized into several groups according to their mechanism of action and chemical structure: Selective Serotonin Reuptake Inhibitors (SSRIs), Serotonin-Norepinephrine...
Antidepressant Drugs: Tricyclics, SSRIs, and SNRIs01:28

Antidepressant Drugs: Tricyclics, SSRIs, and SNRIs

Tricyclic Antidepressants (TCAs), including Desipramine (Norpramin), Imipramine (Tofranil), Clomipramine (Anafranil), and Amitriptyline (Elavil), inhibit serotonin and norepinephrine reuptake and also block other receptors. They are used for depression, pain conditions, and insomnia. Common adverse effects include anticholinergic effects, sedation, orthostatic hypotension, and weight gain. They have a narrow therapeutic window and so require plasma-level monitoring. Abrupt discontinuation can...
Electroconvulsive Therapy01:30

Electroconvulsive Therapy

Electroconvulsive therapy (ECT), or shock therapy, remains a critical biomedical intervention for severe, treatment-resistant depression. While its origins can be traced back to Hippocrates' observations that malaria-induced convulsions alleviated mental illness, modern ECT has evolved significantly from its earlier, more primitive applications. First introduced in 1938 by Ugo Cerletti and his colleagues, ECT involves inducing controlled seizures using electrical currents. In its early years,...
Depressive Disorders: MDD and Dysthymia01:27

Depressive Disorders: MDD and Dysthymia

Depressive disorders are a group of mental health conditions characterized by pervasive feelings of sadness, diminished pleasure in life, and a significant impact on daily functioning. These conditions are most prevalent in individuals during their 30s and affect women at twice the rate of men. Contrary to popular belief, younger individuals are generally more susceptible to these disorders than older adults. Two key types of depressive disorders include Major Depressive Disorder (MDD) and...
Drug Therapy01:28

Drug Therapy

The advent of drug therapy has profoundly shaped modern mental health care, providing targeted treatments for a range of psychological disorders. Psychotherapeutic drugs, classified into antianxiety, antidepressant, and antipsychotic medications, address symptoms across anxiety disorders, mood disorders, and schizophrenia. While these medications have transformed patient outcomes, they require careful management due to their potential side effects and limitations.
Antianxiety Medications